Safety and Immunogenicity of Adjuvanted Recombinant Subunit Herpes Zoster Vaccine in Lung Transplant Recipients.

Hirzel, Cedric; L'Huillier, Arnaud G; Ferreira, Victor H; Marinelli, Tina; Ku, Terrance; Ierullo, Matthew; Miao, Congrong; Schmid, D Scott; Juvet, Stephen; Humar, Atul; Kumar, Deepali (2021). Safety and Immunogenicity of Adjuvanted Recombinant Subunit Herpes Zoster Vaccine in Lung Transplant Recipients. American journal of transplantation, 21(6), pp. 2246-2253. Wiley-Blackwell 10.1111/ajt.16534

[img] Text
ajt.16534__1_.pdf - Accepted Version
Restricted to registered users only until 11 February 2022.
Available under License Publisher holds Copyright.

Download (12MB) | Request a copy
[img] Text
ajt.16534.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

Lung transplant recipients are at high risk for herpes zoster and preventive measures are a significant unmet need. We investigated the safety and immunogenicity of two doses of a recombinant zoster vaccine (RZV) in lung transplant recipients (≥50 years). We enrolled 50 patients of which 49 received at least one vaccine dose. Anti-glycoprotein E (gE) antibody levels (n=43) increased significantly compared to baseline (median optical density [OD] 1.96; interquartile range [IQR]: 1.17-2.89) after the first (median OD 3.41, IQR 2.54-3.81, p<0.0001) and second vaccine dose (median OD 3.63, IQR 3.39-3.86, p<0.0001). gE-specific polyfunctional CD4+ T-cell frequencies (n=38) also increased from baseline (median 85 per 106 CD4+ T-cells; IQR: 46-180) to the first (median 128 per 106 CD4+ T-cells; IQR: 82-353; p=0.023) and after the second dose (median 361 per 106 CD4+ T-cells; IQR: 146-848; p<0.0001). Tenderness (83.0%; 95%CI:69.2-92.4%) and redness (31.9%; 95%CI:19.1-47.1%) at injection site were common. One rejection episode within three weeks of vaccination was observed. This is the first study demonstrating that RZV was safe and elicited significant humoral and cell mediated immunity in lung transplant recipients. RZV is a new option for the prevention of shingles in this population.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Hirzel, Cédric

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1600-6135

Publisher:

Wiley-Blackwell

Language:

English

Submitter:

Annelies Luginbühl

Date Deposited:

19 Apr 2021 12:29

Last Modified:

06 Jun 2021 01:33

Publisher DOI:

10.1111/ajt.16534

PubMed ID:

33565711

BORIS DOI:

10.7892/boris.152217

URI:

https://boris.unibe.ch/id/eprint/152217

Actions (login required)

Edit item Edit item
Provide Feedback